International Assets Investment Management LLC Buys Shares of 22,809 Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

International Assets Investment Management LLC bought a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor bought 22,809 shares of the company's stock, valued at approximately $11,070,000.

A number of other institutional investors have also bought and sold shares of AMPH. TD Asset Management Inc raised its position in shares of Amphastar Pharmaceuticals by 67.4% during the second quarter. TD Asset Management Inc now owns 1,691,569 shares of the company's stock valued at $67,663,000 after buying an additional 680,976 shares during the last quarter. Millennium Management LLC grew its stake in Amphastar Pharmaceuticals by 84.6% during the second quarter. Millennium Management LLC now owns 738,748 shares of the company's stock valued at $29,550,000 after acquiring an additional 338,653 shares in the last quarter. Epoch Investment Partners Inc. increased its holdings in Amphastar Pharmaceuticals by 35.1% in the 2nd quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company's stock valued at $43,154,000 after acquiring an additional 280,390 shares during the last quarter. Marshall Wace LLP purchased a new stake in Amphastar Pharmaceuticals in the 2nd quarter worth $9,085,000. Finally, American Century Companies Inc. boosted its holdings in shares of Amphastar Pharmaceuticals by 19.7% during the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company's stock valued at $29,616,000 after purchasing an additional 121,764 shares during the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

Insiders Place Their Bets

In other news, EVP Rong Zhou sold 4,000 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the sale, the executive vice president now owns 118,388 shares of the company's stock, valued at approximately $5,724,059.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, Director Richard K. Prins sold 17,101 shares of the firm's stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $43.07, for a total transaction of $736,540.07. Following the completion of the sale, the director now directly owns 33,971 shares of the company's stock, valued at approximately $1,463,130.97. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Rong Zhou sold 4,000 shares of the business's stock in a transaction on Monday, August 26th. The shares were sold at an average price of $48.35, for a total value of $193,400.00. Following the transaction, the executive vice president now owns 118,388 shares of the company's stock, valued at approximately $5,724,059.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 24,101 shares of company stock valued at $1,069,350 over the last three months. 27.10% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

AMPH has been the topic of several research reports. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. StockNews.com raised Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Friday, October 18th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $63.00.

Amphastar Pharmaceuticals Price Performance

Shares of NASDAQ AMPH traded down $0.25 during mid-day trading on Thursday, hitting $50.53. 266,346 shares of the company's stock traded hands, compared to its average volume of 392,856. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.52 and a quick ratio of 2.63. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92. The company's 50-day moving average is $48.17 and its two-hundred day moving average is $43.72. The company has a market capitalization of $2.47 billion, a P/E ratio of 17.57, a PEG ratio of 0.88 and a beta of 0.83.

Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported $0.85 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.10. The firm had revenue of $182.39 million during the quarter, compared to analysts' expectations of $171.29 million. Amphastar Pharmaceuticals had a return on equity of 29.79% and a net margin of 23.36%. On average, equities analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.71 EPS for the current fiscal year.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.